ANA4CKD - Randomized multicenter double-blind controlled trial comparing anakinra to prednisone for gout flare in patients with chronic kidney disease stage 4-5 or kidney transplantation

Men and women over 18 years of age with renal failure renal failure stages 3b/4/5, renal transplantation or dialysis and an untreated gout attack

The main evaluation criterion will be the change in pain between the day of inclusion and 3 days after initiation of treatment (D3) or the day of discharge from hospitalization if this occurs before D3.

Efficacy of anakinra: To compare changes in pain from baseline to D5, Efficacy of anakinra: To compare speed of resolution of attacks(>80% improvement or pain less than 20 mm), Efficacy of anakinra: To compare treatment response time (more than 50% improvement), Efficacy of anakinra: To compare duration of treatment, Efficacy of anakinra: To compare number of responders (improvement at D3), Efficacy of anakinra: To compare the number of relapses during the study month of the study, • Efficacy of anakinra: To compare consumption of care during the month of the study: length of hospital stay, use of analgesics, length of time off work, Tolerance of anakinra: To compare injection-site reactions, Tolerance of anakinra: To compare decreases in neutrophils or platelets, Tolerance of Anakinra: To compare severe infections, Tolerance of anakinra: To compare decompensation of comorbidities: HTA, diabetes, dyslipidemia, obesity, CKD, •- Tolerance of anakinra: To compare cardiovascular events: myocardial infarction myocardial infarction, arrhythmia, heart failure relapse heart failure, stroke

No related papers found yet.

France